Cargando…

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion

The PET ligand [(18)F]AV‐1451 was developed to bind tau pathology in Alzheimer's disease, but increased binding has been shown in both genetic tauopathies and in semantic dementia, a disease strongly associated with TDP‐43 pathology. Here we assessed [(18)F]AV‐1451 binding in behavioral variant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bevan‐Jones, Richard W., Cope, Thomas E., Jones, Simon P., Passamonti, Luca, Hong, Young T., Fryer, Tim, Arnold, Robert, Coles, Jonathan P., Aigbirhio, Franklin A., Patterson, Karalyn, O'Brien, John T., Rowe, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186940/ https://www.ncbi.nlm.nih.gov/pubmed/30349864 http://dx.doi.org/10.1002/acn3.631

Ejemplares similares

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
por: Bevan-Jones, W R, et al.
Publicado: (2018)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

In vivo PET imaging of neuroinflammation in familial frontotemporal dementia
por: Malpetti, Maura, et al.
Publicado: (2021)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
por: Bevan-Jones, W Richard, et al.
Publicado: (2020)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia
por: Malpetti, Maura, et al.
Publicado: (2023)

Synaptic density in carriers of C9orf72 mutations: a [(11)C]UCB‐J PET study
por: Malpetti, Maura, et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

In vivo evidence for pre‐symptomatic neuroinflammation in a MAPT mutation carrier
por: Bevan‐Jones, W. Richard, et al.
Publicado: (2019)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

Cortical Complexity Analyses and Their Cognitive Correlate in Alzheimer’s Disease and Frontotemporal Dementia
por: Nicastro, Nicolas, et al.
Publicado: (2020)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia
por: Fratta, Pietro, et al.
Publicado: (2013)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions
por: Mahoney, Colin J, et al.
Publicado: (2012)

C9ORF72 Repeat Expansion in Australian and Spanish Frontotemporal Dementia Patients
por: Dobson-Stone, Carol, et al.
Publicado: (2013)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion
por: Downey, Laura E, et al.
Publicado: (2012)

Assessment of psychiatric changes in C9ORF72 frontotemporal dementia
por: Hornberger, Michael
Publicado: (2012)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses
por: Bevan-Jones, W Richard, et al.
Publicado: (2017)

Synaptic Loss in Frontotemporal Dementia Revealed by [ (11)C]UCB‐J Positron Emission Tomography
por: Malpetti, Maura, et al.
Publicado: (2022)

Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72
por: Boeve, Bradley F., et al.
Publicado: (2012)

Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features
por: Mahoney, Colin J., et al.
Publicado: (2012)

The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion
por: Devenney, Emma M, et al.
Publicado: (2016)

Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
por: Trageser, Kyle J., et al.
Publicado: (2019)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_695om98ebsr9lsupuajciaehfv